Analyzing CareDx (NASDAQ:CDNA) & GETINGE (OTCMKTS:GNGBY)

CareDx (NASDAQ:CDNA) and GETINGE (OTCMKTS:GNGBY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Risk & Volatility

CareDx has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, GETINGE has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Profitability

This table compares CareDx and GETINGE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CareDx	19.79%	21.16%	14.25%
GETINGE	4.15%	10.24%	5.40%

Analyst Ratings

This is a summary of recent ratings and recommmendations for CareDx and GETINGE, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0	2	4	0	2.67
GETINGE	0	1	0	0	2.00

CareDx currently has a consensus price target of $30.33, indicating a potential upside of 57.99%. Given CareDx’s stronger consensus rating and higher possible upside, equities analysts plainly believe CareDx is more favorable than GETINGE.

Earnings and Valuation

This table compares CareDx and GETINGE”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$333.79 million	3.20	$52.55 million	$1.15	16.70
GETINGE	$3.29 billion	N/A	$154.96 million	$0.51	37.72

GETINGE has higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than GETINGE, indicating that it is currently the more affordable of the two stocks.

Summary

CareDx beats GETINGE on 8 of the 11 factors compared between the two stocks.

About CareDx

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

About GETINGE

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions. The company also provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, and drainage solutions; and operating room infrastructure equipment, anesthesia, advanced patient monitoring, operating room management, and operating room integration solutions. In addition, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices; bioreactor systems, DPTE systems, Getinge isolators, terminal sterilization products, and sterilizers; and vivarium, biohazardous materials handling solutions, labware cleaning and sterilization, upstream bioprocessing, and bioreactor preparation solutions. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.